This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

New Biomarkers & Endpoints in HBV | Room 716

Thursday, June 14, 2018
4:15 PM to 6:00 PM

Chairs: Blaine Hollinger & Seng Gee Lim

Invited Presentations:

 4:15pm

The value of HBsAg quantification in the natural history and treatment of HBV Henry Chan, The Chinese University Of Hong Kong, Hong Kong

4:40pm
Choosing the right endpoint for HBV treatment Jean Michel Pawlotsky, Henri Mondor University Hospital, Creteil

5:05pm
New Biomarkers for HBV infection Harry Janssen, Toronto Centre for Liver Disease, Toronto

Oral Abstracts:

5:30pm
Utility of a new HBV RNA assay in HBeAg positive and negative CHB and following HBsAg seroclearance in patients treated with ARC-520, an RNAi drug targeting cccDNA derived HBV mRNA Emily Butler, Abbott Diagnostics, Chicago

5:45pm
HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B and its relation to other serum viral biomarkers Mina Farag, Toronto Center For Liver Disease, Toronto